Ankylosing Spondylitis, AS, is a chronic, inflammatory, self-immunological disease that mainly affects the spinal column and the hip, causing pain, rigidity and functional impairment. Biological agents have been widely used clinically in recent years as an important tool for the treatment of direct spina. This paper will explore the selection of biological agents for high-relative spinal disease and their associated concerns. # Common biological agent type 1. Anti-tumour necrosis # Resistants are the biological agents most commonly used in the current treatment of direct spinal disease, which improves the condition by inhibiting the biological activity of the cause of tumour necrosis and disrupting the inflammatory response of its involvement. The commonly used TNF-alpha resistant agents include:
Inácip: is an integrated protein, reversible in combination with TNF-α, inhibiting its immune response. For patients over 18 years of age with active direct spinal disease.
Adam is a single anti-drug, which is similar to Inasip but less immune. It is applied to active and direct polio patients who are not effective in conventional or traditional treatment.
Inflisi is a single anti-drug, which applies to persons with moderate and high-intensity straight spinal diseases, especially in cases where mid-axis joints are tired and routine treatment is ineffective.
2. Whites-17 (IL-17) stressor Whites-17 stressor, e.g., a single anti-injection in Sukuchio, reduces inflammation response by inhibiting the biological activity of IL-17, and improves the condition of the direct spina column.
The JAK inhibitor, such as the Bariteni tablet, acts as an anti-inflammatory function by inhibiting the activity of Janus Thrust (JAK) and disrupting the transmission of cytogens signals. JAK inhibitors are also used for the treatment of direct spinal disease.
Principles of selection of biological agents:
1. In the selection of biological agents, a comprehensive assessment of the patient ‘ s condition, including symptoms, signs, inflammation indicators (e.g., blood sank, C-reactive protein) and image performance, is required. Biological agents are the preferred treatment for patients with severe conditions, high levels of inflammation and rapid progress.
2. Drug characteristics. Different types of biological agents have different mechanisms of operation and efficacy characteristics. When choosing a drug, it is necessary to take into account the specific circumstances of the patient, such as age, gender, syndrome, etc., as well as the side effects of the drug, price, etc. 3. Economic capacity. Bioagents are relatively expensive and require long-term treatment. Therefore, in the selection of biological agents, due consideration needs to be given to the financial capacity of the patient and to avoid imposing an excessive financial burden on the patient.
Attention
1. Side-effect monitoring Biological agents, while having significant therapeutic effects, may also have some side effects, such as infection, allergies, etc. Therefore, there is a need to closely monitor changes in the patient ‘ s condition during treatment and to adjust the treatment programme in a timely manner.
2. Subject to medical advice, the use of biological agents shall be carried out under the guidance of a doctor, avoiding the use of self-medicines or altering the dose of the drug. At the same time, periodic reviews are required to assess the effectiveness and safety of treatment.
3. Comprehensive treatment Biological agents are one of the most important but not the only means of treating acute spinal disease. In the course of treatment, the patient ‘ s specific situation needs to be taken into account in combination with other treatments, such as anti-inflammation drugs, physiotherapy, rehabilitation exercise, etc., in order to achieve optimal treatment.
Conclusions
It is a chronic, inflammatory self-immunological disease, and biological agents are widely used clinically as one of the important means of treating it. The selection of biological agents requires a combination of assessment of the patient ‘ s condition, drug properties and financial capacity. At the same time, changes in the patient ‘ s condition need to be closely monitored and treated in accordance with medical instructions in order to achieve optimal treatment.
